Medicare

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug...

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision...

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...

Lightbeam Health Solutions and Wakely Consulting Group Partner to Launch Predictive ACO Optimization Tools for Value-Based Care Leaders

New partnership empowers ACOs to drive millions in value through network performance benchmarking and predictive actuarial insights DALLAS, Nov. 19,...

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Azara Healthcare Releases New Risk Adjustment Capabilities in EHR Plug-In for athenaOne via the athenahealth Marketplace

New Functionality Streamlines RAF Gap Closure at the Point of Care, Boosting Documentation Accuracy and Streamlining Workflows BURLINGTON, Mass., Nov....

MDaudit’s 2025 Benchmark Report Reveals Ongoing Acceleration of Payer Audits, Troubling Rise in Denials and Outpatient Coding Issues

Annual analysis points to an urgent need to redefine revenue integrity as proactive protection, while strengthening coding integrity and denial...

error: Content is protected !!